The results indicated that a lower GLP-1 signaling score was related to more effective response and a better clinical outcome in patients with urothelial carcinoma (GSE61676) and non-small cell lung cancer (GSE61676 and GSE135222) (Figure 10). This evidence concerns the gene GCG and non-small cell lung carcinoma.